Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer

Tumor microenvironment: The culprit for ovarian cancer metastasis?

(2016) Zhongyue Luo et al.   CANCER LETTERS

The urgent need to recover MHC class I in cancers for effective immunotherapy

(2016) Federico Garrido et al.   CURRENT OPINION IN IMMUNOLOGY

PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer

(2016) John R. Webb et al.   GYNECOLOGIC ONCOLOGY

Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application

(2016) Masaki Mandai et al.   International Journal of Clinical Oncology

PD-L1 expression in human cancers and its association with clinical outcomes

(2016) Jinming Yu et al.   OncoTargets and Therapy

Adoptive immunotherapy against ovarian cancer

(2016) Gloria Mittica et al.   Journal of Ovarian Research

NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?

(2016) Claudia Cantoni et al.   Journal of Immunology Research

Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non–Small-Cell Lung Cancer

(2015) Satoru Kitazono et al.   Clinical Lung Cancer

Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

(2015) Junzo Hamanishi et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

limma powers differential expression analyses for RNA-sequencing and microarray studies

(2015) Matthew E. Ritchie et al.   NUCLEIC ACIDS RESEARCH

KEGG as a reference resource for gene and protein annotation

(2015) Minoru Kanehisa et al.   NUCLEIC ACIDS RESEARCH

Why weight? Modelling sample and observational level variability improves power in RNA-seq analyses

(2015) Ruijie Liu et al.   NUCLEIC ACIDS RESEARCH

Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome

(2015) Katharina Auer et al.   Oncotarget

Skeletal Muscle Depletion and Markers for Cancer Cachexia Are Strong Prognostic Factors in Epithelial Ovarian Cancer

(2015) Stefanie Aust et al.   PLoS One

Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype

(2014) Federico Garrido et al.   INTERNATIONAL JOURNAL OF CANCER

The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity

(2014) Suzanne Ostrand-Rosenberg et al.   JOURNAL OF IMMUNOLOGY

Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium

(2013) Anna Bachmayr-Heyda et al.   BMC CANCER

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

(2013) M. Sznol et al.   CLINICAL CANCER RESEARCH

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer

(2010) Melissa A. Geller et al.   CYTOTHERAPY